CEL-SCI Corporation is a biotechnology company focused on the research and development of immunotherapy products for treating cancer, autoimmune, and infectious diseases. Its primary investigational therapy, Multikine®, aims to enhance the body's immune response against tumors. CEL-SCI engages in drug discovery, development, and manufacturing of complex biological substances, serving patients and healthcare providers in the oncology sector. The company operates primarily in the United States and is involved in clinical trials to evaluate the efficacy of its therapies.
- Website
- cel-sci.com
- Issuer profile
- All listings